NovaBridge Biosciences: capex
| Value | {"amount": 1599000, "concept": "us-gaap:PaymentsToAcquirePropertyPlantAndEquipment", "currency": "USD"} |
|---|---|
| Period | 2023-01-01 – 2023-12-31 |
| Status | superseded |
| Entity | NovaBridge Biosciences |
Provenance
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
Retrieved: 2026-08-19T18:00:48.227251+02:00
Raw response sha256:
Also addressable by official identifiers:
Cite as: FACTANKER, https://factanker.com/fact/ab65b5f7-d22a-43bc-a00d-2af9f1df788e
Source: SEC EDGAR CompanyFacts (US-PD-17USC105)
Reference:
0001104659-24-054452Retrieved: 2026-08-19T18:00:48.227251+02:00
Raw response sha256:
f7bde1a401b286c74a2fd824ee1df541…Also addressable by official identifiers:
https://factanker.com/fact/sec/cik-0001778016/capex/2023-12-31 (CIK, metric, reporting date)Cite as: FACTANKER, https://factanker.com/fact/ab65b5f7-d22a-43bc-a00d-2af9f1df788e
History
- supersedes {"unit": "CNY", "value": 11351000, "concept": "us-gaap:PaymentsToAcquirePropertyPlantAndEquipment"} (evidence 0001104659-24-054452)